Crucell « Terug naar discussie overzicht

PB-Antilichamen tegen H5N1 ontdekt

145 Posts, Pagina: 1 2 3 4 5 6 7 8 » | Laatste

Omlaag ↓

[verwijderd] 27 september 2007 23:04

Published: 23:00 27.09.2007 GMT+2 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562

Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus. The antibody provides immediate protection and neutralizes the broadest range of H5N1 strains.

Leiden, The Netherlands, September 27, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced the discovery of a set of human monoclonal antibodies against H5N1. These results, demonstrating the potential of human monoclonal antibodies for pandemic preparedness, were presented today at the 5th International Bird Flu Summit held in Las Vegas, Nevada.

A total of twenty one human monoclonal antibodies were discovered. These were found to be able to neutralize the H5N1 virus of avian influenza, which currently presents a global threat. The most potent of the antibodies was shown to neutralize the broadest range of H5N1 strains that have emerged between 1997 and 2004. This antibody may therefore provide a powerful tool in pandemic preparedness. In addition, this antibody prevents flu, in pre-clinical models, when given twenty four hours before a challenge with a lethal dose of highly pathogenic H5N1 virus. When given three days after infection, it also was shown to prevent death and cure the disease.

"Our discovery of potent human monoclonal antibodies against a number of different H5N1 pandemic flu types, provide proof of concept that antibodies are a serious alternative to vaccination or antiviral treatment", said Dr. Jaap Goudsmit, Chief Scientific Officer of Crucell. "What is most encouraging is the fact that these antibodies are not only able to prevent infection, but also open the possibility to treat infected individuals. Treatment with this antibody provides an instantaneous antiviral response, which is an advantage over the delayed immune response after (prepandemic) vaccination."

The set of monoclonal antibodies, which was produced by Crucell researchers using phage display and Crucell PER.C6® technology, showed the potential to neutralize distinct H5N1 viruses, A/Vietnam/11994/04, A/Hong Kong/213/03 and A/Hong Kong/156/97. The antibodies apparently recognize a part of the viral membrane protein that is present among all H5N1 viruses tested. The most potent neutralizing antibody was tested in pre-clinical models for the ability to protect against infection with the highly pathogenic A/Hong Kong/97 H5N1 virus and was also tested for its ability to stop the development of the disease caused by this virus. When the monoclonal antibody was given in a pre-clinical model, one day prior to infection with the H5N1 virus, it resulted in full protection against infection. Treatment with the antibody up to three days after infection, resulted in 100% survival and cure of the disease.

About Pandemic Influenza

Influenza is a highly infectious virus which spreads easily from person to person. In a pandemic, a new and more virulent virus infectious for humans arises with the potential to cause severe disease and high mortality. H5N1 Viruses isolated from wild and domestic birds and from humans since the outbreaks in Hong Kong separate in distinct genetic groups (clade and subclades) of closely related viruses. Clade 1 virus circulated in Cambodia, Thailand and Viet Nam and caused infections in humans in 2004 and 2005. Clade 2 viruses circulated in China and Indonesia in 2003 -2004 and spread to the Middle East, Africa and Europe in 2005 and 2006.

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

voda 27 september 2007 23:11

Dat is rap Redpoint. Staat nu ook op de Crucell site. Hoe is het mogelijk om 11.00 uur s'ávonds?
AB!

miekemuis 27 september 2007 23:15

AB Redpoint, zo juist voor het slapengaan...

Morgen allen gezond weer op en hopelijk met een wat hogere koers de week eindigen met dit nieuws. Op dit moment al 7 aanbevelingen (je ziet, er is nog interesse in Crucell door de "aanhangers")

Slaapwel

[verwijderd] 27 september 2007 23:15

Zo ,zie je hoevaak het artikel hier al gelezen is op dit tydstip!70x in 14 minuten.Hoezo geen intresse meer.

[verwijderd] 27 september 2007 23:16

Voor 100% survival en cure doe ik het voor :)
super!

[verwijderd] 27 september 2007 23:18

GO Crucell GO !!!!!!!!!!!
Een oude kreet kan weer vernieuwd :))))))))))))

Grtz, S (een oude en trouwe fan)

[verwijderd] 27 september 2007 23:19

quote:
Japies schreef:
Voor 100% survival en cure doe ik het voor :)
super!

Goed nieuws!

aossa 27 september 2007 23:24

Voor deskundige commentaar van maxen zie www.iex.nl/forum/topic.asp?forum=228&...

(want nee, ik ga het hier weer niet geheel herhalen).

[verwijderd] 27 september 2007 23:26

En waar is de reactie van Ron Banged.
PS: op zijn kritieken kom ik later terug. Hij is en basher.

voda 27 september 2007 23:27

Al 14 ab's? Zit iedereen te wachten op goed nieuws of zo :-)

[verwijderd] 27 september 2007 23:34

After Hours
Time (ET) After Hours
Price After Hours
Share Volume
17:26 $ 20.85 150
17:26 $ 21 400
17:26 $ 21.15 100
17:08 $ 20.15 200
16:16 $ 19.929 100

Hit 'm Hard!

100% genezing.
Developed in the Netherlands for mankind!

[verwijderd] 27 september 2007 23:38

Zag ik ook.
Zegt mij nog niet zo veel. Lichte vraag in een lege markt????

Bericht is wel mooi.

aossa 27 september 2007 23:39

Slides zie Crucell site:
hugin.info/132631/R/1156548/223246.pdf

voda 27 september 2007 23:42

Is dit eerder gebeurt om zo laat nog een PB te "lanceren"?
Waar is Flosz? (Ja, weg, dat weet ik) :-(

[verwijderd] 27 september 2007 23:42

Hij staat nu op USD 20,15 in de after hours
finance.google.com/finance?client=gd&...

omgerekend is dat ca. EUR14,29.

Ik hoop dat er enig verder koersherstel zal plaatsvinden!

Welterusten =)

edit: hij schiet net omhoog naar 21,15 : ~EUR15!

[verwijderd] 27 september 2007 23:43

100% genezing H5N1.
Trots voert bij mij de boventoon wat Crucell uit Nederland te bieden heeft voor de mensheid.
Super.

diederique 27 september 2007 23:44

latest news on biotech stocks in Market Watch:

Trading higher, U.S.-listed shares of Crucell NV

CRXL 19.90, +0.50, +2.6%) hopped 2% to $20.85.

The Dutch biotech company said its researchers have discovered a monoclonal antibody that appears to be effective against the H5N1 strain of avian influenza. The data will be presented at a medical conference late this month in Las Vegas.

Val Brickates Kennedy is a reporter for MarketWatch in Boston.

[verwijderd] 27 september 2007 23:45

quote:
Japies schreef:
After Hours
Time (ET) After Hours
Price After Hours
Share Volume
17:26 $ 20.85 150
17:26 $ 21 400
17:26 $ 21.15 100
17:08 $ 20.15 200
16:16 $ 19.929 100

Hit 'm Hard!

100% genezing.
Developed in the Netherlands for mankind!

In case you are wondering, I am here. I am still amused that there are some who think I am a basher in any sense except I hate incompetence, especially of upper management. Always loved Jaap, who seems to carrying this company on his shoulders.

The after hours "Bid" price on E-Trade is now $22.50, with the "ask" price of $25.00

aossa 27 september 2007 23:45

quote:
Japies schreef:
100% genezing H5N1.
Trots voert bij mij de boventoon wat Crucell uit Nederland te bieden heeft voor de mensheid.
Super.

En zeker als men weet dat ze daar in de 20e eeuw nog op klompen liepen ;-)

Gefeliciteerd noorderburen !

Volare ... Cantare ... Ohhhh Oh Oh

Mr Greenspan 27 september 2007 23:46

Kan Crucell binnenkort een leuke financiele beloning krijgen hiervoor?

145 Posts, Pagina: 1 2 3 4 5 6 7 8 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 860,01 -5,35 -0,62% 18:05


Germany40^	17.683,90	-0,86%
BEL 20	3.827,75	+0,03%
Europe50^	4.898,59	-0,77%
US30^	37.851,00	-0,43%
Nasd100^	17.004,48	-3,10%
US500^	4.960,22	-1,76%
Japan225^	37.028,48	-2,56%
Gold spot	2.397,18	+0,75%
EUR/USD	1,0651	+0,07%
WTI	82,29	+0,26%